key: cord-0922014-d9xxv8dh
authors: Mudiaga Etaware, Peter
title: Virtual system for early detection of COVID-19 infection “Etaware-CDT-2020 prototype design” (corroborated by rRT-PCR data)
date: 2021-11-17
journal: Biomed Signal Process Control
DOI: 10.1016/j.bspc.2021.103337
sha: 8cf7e00fcbc9b94ca58e8e42a5775cfd6ad6d381
doc_id: 922014
cord_uid: d9xxv8dh

The 2(nd) phase of COVID-19 infection outbreak experienced worldwide is an attestation to the decline in the efficiency of COVID-19 detection kits available worldwide. rRT-PCR still remains the best confirmatory test for COVID-19 infection. Sadly, most medical professionals are not conversant with the rRT-PCR protocols. Therefore, more easy-to-use alternatives are required as backup, to compensate for these lapses. “Etaware-CDT-2020” is a virtual system designed for early detection of COVID-19 infection. A comparative COVID-19 diagnosis was conducted by Etaware-CDT-2020, corroborated by rRT-PCR-confirmed COVID-19 results obtained from China (Latitude 35.8617(o)N and Longitude 104.1954(o)E), which was the epicentre for COVID-19 infection outbreak. A cross-comparison of results showed that there was a positive correlation between the output result from Etaware-CDT-2020 and rRT-PCR diagnosis from Wuhan (r = 0.92) and Hubei (r = 0.97). Furthermore, there was no significant difference between the diagnostic results of “Etaware-CDT-2020” and rRT-PCR, when compared by T-test (P(t=0)>0.05) and Pearson’s Chi-Square test (0.04≥P≤0.12). Etaware-CDT-2020 is unique and can be used anywhere, anytime and by anyone. It is accessible, affordable, easy to install, simple to understand and user friendly.

The novel and deadly Coronavirus disease 2019 , caused by the noxious pathogen "Sars-Cov-2", is a serious threat to global health, due to its ability to mutate and adapt to different hosts (intermediate, collateral, alternate or primary) , their environment and body system (Cortellis, 2020) , combined with the ability to subdue or bypass the complex network of human immune system or defense mechanism(s) (Etaware, 2020a) , resulting in a fleet of new waves of COVID-19 infection around the world (Gorbalenya et al., 2020) . In response to the global insecurity of human lives to infectious diseases (WHO, 2020a), some manufacturers developed easy-to-use rapid immunodiagnostic test (IRT) kits for use in clinics, hospitals and isolation centres (WHO, 2020b) .

Sadly, some of these RIT kits have major defects i.e., their functionality and efficiency were largely affected by the amount and quality of viral protein (Antigens) and antibodies present in respiratory, blood and serum samples of infected patients and those with latent infection Pan et al., 2020; Zhang et al., 2020) .

Clinical diagnosis of COVID-19 infection using rRT-PCR is still the most effective and accurate means of confirming cases of COVID-19 infections all around the world (Etaware, 2020b; Etaware, 2020c) . Unfortunately, the knowledge and application of the most recent rRT-PCR protocols, the management of infected samples, and the operation of the rRT-PCR machine by some medical staff is below average, coupled with the unavailability of BSL-2 facilities in developing and underdeveloped countries of the world. These are some of the major reasons behind the geometric increase in the circulation of "false-positive" COVID-19 results in Africa and some Countries/States in America, Antarctica, Asia, Australia, and Europe, where these medical lapses are highly pronounced. The rising occurrence of COVID-19 infection among medical personnel and most health care providers around the globe, is also a major cause for concern. The involvement of more COVID-19 tests (screening, or detection and confirmatory tests) in countries where rRT-PCR is not readily available is highly recommended. Therefore, this research seeks to juxtapose the results of COVID-19 infection diagnosis in China, confirmed by rRT-PCR, with the diagnosis performed on the same patients by Etaware-CDT-2020 , in order to provide a reliable platform for screening and early detection of COVID-19 infection, prior to confirmation by rRT-PCR. Finally, a plethora of all possible techniques for the diagnosis of COVID-19 infection, can help minimize "false-positive" diagnosis, detect slightest aberration in the disease phenology and further avert the outbreak of new waves of deadly COVID-19 infection outbreak around the world.

Hypothesis (Null): There are no underlying medical or clinical differences existing between the COVID-19 symptoms used as adoptive markers in the programming of "Etaware-CDT-2020" and COVID-19 infection diagnosis in humans. Source: CDC, 2020; Chan et al., 2020; Cortellis, 2020; Guan et al., 2020; Helmy et al., 2020; Huang et al., 2020; Hui et al., 2020; Lin et al., 2020; Mayo clinic, 2020; Pan et al., 2020; Xu et al., 2020 . The following should be Noted: 1. The complementary score (Comp. Score) was pre-defined by the author (Etaware, 2020c) 2. It has no medical or statistical relationship with the symptoms itemized. 3. It is just a guide used by the author to quantify the importance of each symptom to COVID-19 infection, in order to generate a rationale system for screening COVID-19 infections in humans 8 

The levels for COVID-19 infection (Y sars-cov-2 ) was carefully defined by P. M. Etaware © 2020, in line with the corresponding medical condition(s), to aid effective quantification and possible categorization of all COVID-19 cases.

Mathematically, the midpoint (Ŷ sars-cov-2 ) for each COVID-19 infection level was calculated thus:

The input device shown in Fig 2 was designed using an exhaustive list of all identified symptoms of COVID-19 infection affirmed by WHO and coded in the present study as "Adoptive Markers" (as at May, 2020). The primary function of the input device was to collect and store information from prospective patients, and also, to act as a mediating platform between information collected and those analysed i.e., It will serve as a basic guide for prospective patients and a feed-in device for the novel prototype design "Etaware Computer Diagnostic Tool-2020" (or Etaware-CDT-2020). The information on the input device include:

 The patient's identity  Already established COVID-19 symptoms (In categories)

The coding of information from the input device to the prototype system is done by converting clinical facts to figures i.e., every clinical symptom(s) of COVID-19 infection marked under the "YES" column should be coded as "1", while those marked under the "NO" column should be coded as "0", those marked under the "UNSURE" column will be automatically coded as "0" by the prototype system.

The medical records of 4,856 virtual patients were used as primary data for the present study. A total of 57.5% of the patients assessed had fever, 56.7% had dry or chesty cough and 52.5% experienced fatigue (Table 3) , these were the most prominent markers or indicators of the disease. A total of 50.8% of the patients' population experienced Shortness of breath (Dyspnoea) and Muscular aches and Pains (Myalgia), while 54.2% had the chills. Sore throat was common in 51.7% of the patients' population, while other symptoms recorded were within the range of 21-55% of the population of patients under medical observation (Table 3) . A total of 10.83% of the patients were either confirmed dead or in ICU or were suspected to be infected by the disease or just merely having digestive disorders (Table 4 ). One-eighth (12.5%) of the total population were suffering from acute respiratory diseases, whereas, 8.33% of the patients infected with the disease were either confined to the use of mechanized oxygen dispensers or still under conditions of self-sustenance (Table 4 ).

The outbreak of fever among COVID-19 patients was well pronounced in all the districts and provinces of China i.e., 100% occurrence was recorded in Hubei Province (90% in the capital "Wuhan"), 88.7% scattered across 552 hospitals in 30 provincial-levels within China, and 87.3% of COVID-19 patients from the 34 provincial-levels and 23 provinces of China (Table 5 ). There was no comprehensive report of dry or chesty cough among COVID-19 patients in Hubei Province but 80% of patients with this symptom was reported in the provincial capital "Wuhan". The total population of COVID-19 patients with dry cough symptoms across the 23 provinces of China was reported as 58.1% (67.8% from 30 out of the 34 Provincial-levels investigated). Patients with severe gastrointestinal disorders were predominant in Hubei and other parts of China (<40%), while those with severe respiratory distress symptoms were common in China as a whole (<35%) as shown in Table 5 . The data for the virtual samples (120 patients) used for this experiment is available in Supplementary File "S1". ---------1.96  04  04  Abdominal Pain  ---------0.98  02  02  Lack of Appetite  ---------39.71  81  81  Discharged  14  06  06  ---------Critical care  15  07 07 

Etaware-CDT-2020 was modelled using virtual data for healthy, unhealthy (patients infected with other ailments related to COVID-19 infection), and COVID-19 infected patients (See details of model development in Etaware, 2020c) . The model was fitted using the multiple regression equation:

Y sars-cov-2 = -α sars-cov-2 +β 1 X 1 +β 2 X 2 +β 3 X 3 + β 4 X 4 +……+β 26 X 26 + ؏ sars-cov-2

Where, Y sars-cov-2 = COVID-19 Infection status (Response variable) The intercept (α) of the regression equation was calculated thus:

Where, Ŷ sars-cov-2 = The mean value of the response variable Ẋ 1 →Ẋ 26 = The mean value of each predictor

The slopes or gradients (β i ) of the regression equation was calculated by the formula: The equation generated was described thus:

Y sars-cov-2 = -1.09*10 -14 +20(X 1 )+20(X 2 )+20(X 3 )+2(X 4 )+2(X 5 )+2(X 6 )+2(X 7 )+2(X 8 )+2(X 9 )+2(X 10 )

+2(X 11 )+2(X 12 )+2(X 13 )+2(X 14 )+2(X 15 )+X 16 The model statistics for Etaware-CDT-2020 was defined in Table 6 . The proportion of variance in the response variable "Y sars-cov-2 " was determined by coefficient of determination (R 2 ) described by the formula:

The coefficient of correlation (standardized covariance), the adjusted-and predictive R 2 for the regression model was calculated thus:

Where, R 2 = The coefficient of determination

Where, n = The sample size, k = The number of predictors, and R 2 = The coefficient of determination

Where, PRESS = The predicted residual error sum of squares, R 2 = The coefficient of determination, and SS total = The total sum of squares

The model statistics showed that R =1.00, R 2 =1.00, Adj. R 2 =1.00 and Pred. R 2 =1.00, respectively ( Table 6 ). The accuracy of Etaware-CDT-2020 was rated as 98. Correction factor --

The data is available in Supplementary File "S3"

The test for multicollinearity among the predictors or independent variables used in structuring the regression model (prototype) was measured by the variable inflation factor (VIF) and tolerance limit (T). "VIF" and "T" were described by the formulae below:

The coefficient of determination used in this equation (R 2 ) was calculated from the ordinary least square regression equation (OLSRE) described thus: X i (if X i = X 1 ) = -α sars-cov-2 +α 2 X 2 +α 3 X 3 + α 4 X 4 +……+α 26 X 26 + ؏ sars-cov-2

Where, X i = X 1 , X 2 , X 3 , ……… X n If VIF (β i ) > 10, then the multicollinearity level of that independent variable compared to other variable is very high and it affect the prediction efficiency of the model whenever a slight change is made to the predictors. The primary data used for the estimation of VIF and T can be found in Supplementary File "S1".

Ordinary least square regression equation VIF (β 2 ) = 2.02 and T = 0.50 (VIF (β 2 ) < 5, "X 2 " is independently associated with other variables)

Ordinary least square regression equation X 3 = 0.16 + 0.04X 1 + 0.16X 2 + 0.28X 4 + 0.35X 5 -0.036X 6 ………………… -0.11X 25 VIF (β 9 ) = 9.94 and T = 0.10 (VIF (β 9 ) < 10, "X 9 " is independently associated with other variables)

Ordinary least square regression equation X 10 = 0.03 + 0.04X 1 … + 0.66X 9 + 0.37X 11 + 0.002X 12 + 0.09X 13 … -0.06X 25 

The collinearity of the data generated by Etaware-CDT-2020 with that obtained from rRT-PCR was tested using the formula: r = n (∑ ) -(∑ )(∑ ) x = data generated by Etaware-CDT-2020 y = data obtained from the corresponding rRT-PCR file

The collinearity test showed that there was a positive relationship between the COVID-19 diagnosis conducted by Etaware-CDT-2020 and those reported by Hui et al. (2020) , for Wuhan patients (r = 0.92) and Pan et al. (2020) , for Hubei patients (r = 0.97), as shown in Tables 7 and 8 (P<0.05) .

However, the correlation between the rRT-PCR COVID-19 diagnostic results and those generated by Etaware-CDT-2020 for patients tested in China was very small (r = 0.19 [Guan et al., 2020] and 0.01 [Cao et al., 2020] , respectively). The data was further compared with the rRT-PCR results using the Pearson chi-square equation described below: Table 7 ) was not significant, therefore, the rRT-PCR diagnostic result was possibly "matched" by the computer diagnosis generated by Etaware-CDT-2020, while that of Hubei patients (X 2 = 11.0, Table 8 ) was significant to those generated by Etaware-CDT-2020 at P≤0.05 (P = 0.07 and 0.04, respectively). The Pearson's chi-square test showed "no significance" difference or disparity in the COVID-19 infection diagnosis conducted and/or generated independently i.e., χ 2 = 22.9 and 23.6, respectively; P = 0.12 and 0.10, respectively, for Chinese patients in general (Tables   9 and 10 The T-test analysis conducted showed that there was no significant difference in the diagnosis carried out by the computer program "Etaware-CDT-2020" and those conducted using the rRT-PCR machine, for both Wuhan and Hubei patients i.e., P(t=0)>0.05 (Tables 7 and 8 ). Fortunately, the Ttest conducted further reaffirmed the results obtained using the Pearson Chi-Square test, as the diagnoses were not significant (P(t=0)>0.05) to those generated by Etaware-CDT-2020 for Chinese patients infected with COVID-19 infection in general (Tables 9 and 10 ). Guan et al. (2020) 

There was perfect elasticity in the distribution curve generated for each pair of COVID-19 diagnosis (rRT-PCR and Etaware-CDT-2020) for the Chinese patients probed by this research (Fig 5-8) . The distribution pattern of the variables represented on each graph was tending towards normality, except those generated by Pan et al., (2020) for Hubei patients (Fig 7) .

The link to the data used in this research is provided in Supplementary File "S6". 

The desired model had a perfect correlation between the epidemiological factors (clinical symptoms) and COVID-19 infection status. Variable coherence (i.e., response variable and predictors) was a major factor pertinent for improving model efficiency as described by . It was observed that the errors of diagnosis or levels of ingenuity of the computer program "Etaware-CDT-2020" was slightly negligible (in some cases) and slightly or totally ambiguous in some situations.

The current rapid computer diagnostic model is very flexible, such that it can be updated to accommodate all manner of COVID-19 cases or medical situations related to COVID-19 infection outbreak globally, if new breakthrough emerges in the frontiers of scientific study of the pathogen's relationship with humans and a compilation of an all-inclusive catalogue of symptoms describing the physiological relationship with the primary host (irrespective of the host gender, age, race or colour). The aforementioned observation was in line with the report given by WHO (2020a WHO ( , 2020b who laid emphasis on the ingenuity in the pathogen's physiological relationship with the host organism (Humans) and the level of mutation, adaptation or transformation of viral genome resulting in a major setback in the development of perfect diagnostic tool and a broad-spectrum treatment or clinical therapy for the novel coronavirus 2019 infection.

The level of similarity between the rRT-PCR and Etaware-CDT-2020 COVID-19 diagnoses were indeed very close. This was further affirmed by the normality of the distribution curves generated for the results. The close proximity in the results showed that Etaware-CDT-2020 was indeed an ideal screening tool for COVID-19 infection. This singular achievement is indeed a huge obeisance to the clarion call by the World Health Organization (WHO, 2020a), who seek to encourage the sharing of data to better understand and thus manage COVID-19 infection outbreak around the world. The development of more useful screening tools or test kits for early detection of COVID-19 infection is a better countermeasure aimed at curtailing the spread of the disease.

The close proximity of the results obtained from Etaware-CDT-2020 to that of the real-time reverse transcription polymerase chain reaction (rRT-PCR), is an indication that Etaware-CDT-2020 can be used as a screening tool for early detection of COVID-19 infection, prior to confirmation with rRT-PCR. For now, the program can be easily installed and used at home, in the office, in public and private clinics, isolation centres, hospitals, schools, hotels, clubs, cinemas, Churches, Mosques etc., without restrictions or contravention to religious or ethical or cultural believes.

I, Peter Mudiaga Etaware solemnly declare that the information provided in this article and the following points itemized below are correct and genuine.

Not Applicable

The corresponding author had the sole right to participate or determine the participant in the current study. All data presented in this report was generated from this research.

All datasets generated or analyzed during the course of this research are included in this article

There are no financial or non-financial competing interest with regards to the research carried out and the publication of this article.

PME was responsible for data acquisition, mining, curation, organization, analysis, interpretation and presentation of results in a logical manner. The conceptualization, manuscript draft, editing, funding, supervision of research and model development was solely done by PME. eruption of skin lesions. In common usage of the term, a "rash" can refer to many different skin conditions. A rash can e caused directly or indirectly by a bacterial. viral, or fungal infection (Murrell and Newman, 2018). 26. Conjunctivitis: An inflammation of the conjunctiva of the eyes (Oxford Dictionary, 2021).

Note: WHO recommend that all patients should be tested for other respiratory diseases using routine laboratory procedures. All patients that meet the suspect-case definition should be tested for COVID-19 virus regardless of whether another respiratory pathogen was found in their specimen sample (WHO, 2020a). 

Fever: An abnormally high body temperature, usually accompanied by shivering, headache, and in severe cases delirium

It is an overall feeling of tiredness or lack of energy i.e., it is a complete state of lack of motivation and energy, both physically and mentally

This is a kind of cough that does not bring up any phlegm or mucus

Muscular aches and pains (Myalgia): Feeling pain in a muscle or group of muscles

Chill/Shivering: Shaking slightly and uncontrollably as a result of being cold, frightened, or excited

Headache: This can be described as the feeling of pain in one or several parts of the head

Loss of appetite: It is a decrease or lack of desire to eat. It is also known as poor appetite or anorexia

Shortness of breath (Dyspnoea): It is a situation where a person experience difficult or laboured breathing

Sore throat: This is the feeling of pain, scratchiness or irritation in the throat, which is most times worsened when you swallow

It is a partial or complete or complete loss of the sense of smell or ability to perceive odours

Loss of sense of taste: This is medically referred to as Ageusia

Nasal congestion: This is a situation where adjacent tissues within the nostrils and blood vessels become swollen with excess fluid, causing a "stuffy" plugged feeling within the nasal cavity

Sometimes it feels crushing or burning, in other cases, the pain travels up the neck, into the jaw, and then radiates to the back or down one or both arms. This is usually caused by poor blood flow to the heart and it is medically known to as angina

Abdominal pain: This is the feeling of crampy, achy, dull, intermittent or sharp pain in the abdomen

Diarrhoea: A condition in which faeces are discharged from the bowels frequently and in a liquid form

Vomiting or Nausea: A feeling of sickness with the ejection of ingested food matter from the stomach through the mouth

Neurological illness: These are diseases of the central and peripheral nervous system. In other words, the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles (WHO

Gastrointestinal illness: These are disease that affect any section of the gastrointestinal tract

Drowsiness: A feeling of being sleepy and lethargic; sleepiness (Oxford Dictionary, 2021) 20. Dizziness: This is a term used to describe a range of sensations, such as, feeling faint, woozy, weak or unsteady. In some cases, it creates the false sense that the individual or his/her surrounding is spinning or moving

Stroke: A stroke, also known as cerebrovascular accident (CVA), occurs when the blood supply to part of the brain is interrupted or reduced, preventing brain cells from getting oxygen and nutrients. Brain cells begin to die shortly after

Pneumonia: This is an infection of the lungs caused by fungi, bacteria, or viruses. General symptoms include chest pain, fever, cough etc

Excess drainage, ranging from a clear fluid to thick mucus, from the nose and nasal passages

Body rash: The word "rash" means a change in the colour and texture of the skin that usually causes an outbreak of red patches or bumps on the skin. It can be defined as a widespread References Biggers, A

What is anosmia? Healthline

Everything you need to know about pneumonia

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis

Centers for Disease Control and Prevention (CDC), 2020. 2019 novel coronavirus

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Climates to travel

Disease briefing: Coronaviruses. A Clarivate Analytics Solution

Medicinal Plants, Synthetic Drugs or Clinical Therapy: The Safest option against the Pandemic COVID-19 Coronavirus

Risk Assessment and Global Sensitization on the Pandemic Spread and Zoonotic Transmission of the deadly COVID-19 Coronavirus Infection

Computational Intelligence methods in COVID-19: Surveillance, prevention, prediction and diagnosis. Studies in computational intelligence book series

ETAPOD: A forecast model for prediction of black pod disease outbreak in Nigeria

Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group

Clinical characteristics of 2019 novel coronavirus infection in China

The COVID-19 Pandemic: A Comprehensive Review of Taxonomy

Clinical features of patients infected with 2019 novel coronavirus in

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -the latest 2019 novel coronavirus outbreak in Wuhan

What is causing this headache?

Evaluation of serological tests in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak

Diagnostic indexes of a rapid IgG/IgM combined antibody test for SARS-CoV-2

Causes of fatigue and how to manage it

Mayo Clinic Book of Home Remedies. Mayo foundation for Medical Health and Research

Stroke; Sore throat; Nasal congestion

02351635#:~:text=A%20sore%20thraot%20is%20pain,virus%20resolves%20on%20its%2 0own

What is causing my rash?

Oxford Languages

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Gastrointestinal diseases

Your abdominal pain and how to treat it

Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases

Advice on the use of point-of-care immunodiagnostic tests for COVID-19. Scientific brief

Rhinorrhoea; Human body temperature; Loss of sense of taste

Mental health: neurological disorders

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

What can cause a dry cough? Medical News Today

Evaluation of recombinant nucleocapsid and spice protein serological diagnosis of novel coronavirus disease 2019 (COVID-19)

Supplementary File "S1". The virtual data used in programming Etaware

Summary of rRT-PCR data of COVID-19 patients from China Supplementary File "S3". Etaware-CDT-2020 program statistics Supplementary File "S4

Posthoc analysis for comparative diagnosis of COVID-19 infection Supplementary File "S6". The link to all the data used in this research

This is to affirm that: Dr Peter M. Etaware received no funding or financial benefits from any private or public organization for this research. infection, by way of providing the populace with personal detection tools that can be stored on their electronic gadgets, in order to increase the chances of the COVID-19 detection. Furthermore, Etaware-CDT-2020 is unique such that it can be used anywhere and anytime by anyone.